Glycosite-specific conjugation has emerged as a gold standard for developing next-generation Antibody-Drug Conjugates (ADCs) and other XDCs. However, most existing approaches are hindered by ...

LOTTE BIOLOGICS (CEO James Park) and SK pharmteco (CEO Joerg Ahlgrimm) announced that they have signed a Letter of Intent ...

Grit Biotherapeutics Co., Ltd. ("Grit Bio"), a leading clinical-stage biopharmaceutical company pioneering next-generation ...

Without such a framework, the language risks continued fragmentation, inconsistent development, and limited functionality in ...

Celonic and Carbogen Amcis partner to provide fully integrated, end-to-end ADC development and manufacturing solutions.

Beijing Tsingke Biotech Co., Ltd., a pioneer in molecular manufacturing, showcased its next-generation integrated ...

SK pharmteco and LOTTE BIOLOGICS have announced that they have signed a Letter of Intent (LOI) for a strategic collaboration ...

GSK has boosted its pipeline of antibody-drug conjugates for cancer, licensing a prostate cancer candidate from Syndivia in a ...

Syngene International, a global CRDMO, is adding a GMP bioconjugation suite at its commercial biologics facility [Unit 3] in Bengaluru. With this new capability, Syngene will offer fully integrated, ...

Syngene expands its Biologics facility in Bengaluru, adding ADC bioconjugation to accelerate development timelines and enhance services.

Given the critical importance of endocytosis detection in ADC research and development, ACROBiosystems has designed an ...

Alphamab Oncology (stock code: 9966.HK) announced that the biparatopic HER2-targeting antibody-drug conjugate (ADC) JSKN003 has been granted Fast Track Designation (FTD) by the U.S. Food and Drug ...